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Capsule  
The ovarian reserve is moderately reduced by first-line gonadotoxic treatment in young cancer 
patients under the age of 18 years requiring fertility preservation prior to treatment of relapse.   
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Abstract 
Objective: To study the impact of first-line antineoplastic treatment on the ovarian reserve in 
young girls returning for ovarian tissue cryopreservation (OTC) in connection with a relapse.  
Design: Retrospective case-control study. 
Setting: Two university hospitals. 
Patients: 63 girls under the age of 18 years who underwent OTC before (group 1: 31 patients) and 
after (group 2: 32 patients) initial cancer treatment.  
Intervention(s): None. 
Main Outcome Measure(s): Follicular densities (follicles/mm3) measured from an ovarian cortical 
biopsy before OTC. The ovarian volume (ml) of entire ovaries excised for OTC was also monitored.  
Results: There was no significant difference in mean age and in follicular density between group 1 
and group 2. In contrast, ovarian volume and total number of ovarian cortex chips cryopreserved 
were significantly lower in patients who received gonadotoxic treatment before OTC (ovarian 
volume 5.3 ±3.1 ml vs 2.9 ±2.1 ml (mean ±SD), p=0.02), number of cortex chips: 21.3 ±8.1 vs 15.2 
±7.1, (mean ±SD), p=0.02). The reduction in the estimated ovarian reserve ranged from 10-20% in 
children to around 30% in adolescent girls (> 10 years).   
Conclusion: Girls under the age of 10 tolerate a gonadotoxic insult better than adolescents, who 
may experience up to a 30% reduction in the ovarian reserve by first line gonadotoxic treatment, 
which today is considered having little effect on the follicle pool. This information will improve 
counselling of young female cancer patients, to decide for fertility preservation or not. 
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Introduction 
During the last 50 years, children and adolescents diagnosed with cancer have progressed from 
having a serious potentially fatal disease to having a most often curable disease. The five-year 
survival for all cancer types is estimated to be more than 80% in both children and adolescents (1). 
Furthermore, the late-effect mortality from any cause has significantly decreased across the last 
decades among five-year survivors of childhood cancer according to the Childhood Cancer Survivor 
Study (2). This success comes from a remarkable development of effective therapeutic regimens, 
including alkylating agent-based chemotherapy and radiotherapy.  
This progress has created an awareness of quality of life aspects after cancer highlighting that the 
successful treatment may compromise fertility after recovery (3). The pool of ovarian follicles that 
constitute the reproductive potential of a girl may be severely reduced or disappear as a 
consequence of the treatment required (4). In prepubertal girls the only available option to 
preserve fertility is to cryopreserve ovarian tissue (5, 6). If ovarian activity is destroyed and 
premature ovarian insufficiency (POI) occurs in young female survivors, cortical ovarian tissue 
might be transplanted to restore ovarian function either for fertility purposes (7, 8) Recently, the 
first child being born after transplantation of ovarian tissue that was harvested before menarche 
was reported (9).    
However, it is often difficult to decide whether it is necessary for a young girl with a cancer disease 
to undergo an invasive procedure to obtain ovarian tissue for fertility preservation. The fertility 
preservation intervention is recommended when there is an estimated risk of POI exceeding 50% 
(10, 11). Ovaries from girls and young women contain very high numbers of follicles and may 
tolerate a relatively high gonadotoxic insult without losing all follicles (12). In most cases 
treatment is initiated with low risk regimens but if more aggressive treatment is needed, 
harvesting ovarian tissue for fertility preservation will be considered. The question therefore arises 
as to whether ovarian tissue cryopreservation (OTC) should be considered in connection with the 
first line treatment such as ABVD, which is often considered to cause a relatively mild gonadotoxic 
insult. Thus, what is the potential gonadotoxic insult caused by the first-line treatment on the 
fertility potential in prepubertal girls and adolescents?  
To answer this question the present study evaluated the follicular density and ovarian volume in 
our cohort of young girls below the age of 18 years with respect to whether or not they had 
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received gonadotoxic treatment before OTC.  
 
Material and Methods 
Patients 
This retrospective study included a total of 63 girls younger than 18 years (range: 1.5 –17.9 years) 
diagnosed with a cancer and referred to one of the three centers that participate in the Danish 
program for fertility preservation by OTC, between year 2002 and 2014. The number of patients 
who had not received chemotherapy prior to oophorectomy was 31 (group 1), while a total of 32 
patients (group 2) had received gonadotoxic treatment before ovarian excision. All patients in 
group 2 had been treated for an original oncological diagnosis, had experienced a relapse and 
underwent OTC prior to further treatment. Patients were only included if a biopsy of the ovarian 
cortex was spared for histology in connection with OTC.  
 
Procedure  
The ovarian cortex was isolated by manual dissection and cut into pieces of approximately 5 x 5 
mm and 1 mm thickness and frozen by slow-freezing technique as previously described (13, 14). A 
small ovarian cortical biopsy (≈ 2x2x1 mm) is routinely taken for histological examination before 
freezing. The piece was processed for histology, cut into 30-µm sections, and stained with 
periodic-acid Schiff reagents and Mayer hematoxylin. The follicular density, follicles per mm3, was 
calculated by counting all types of follicles in every second section as previously described (15). 
Since one entire ovary was removed, the ovarian volume was recorded by weighing the tissue prior 
to preparation for cryopreservation. The density of ovarian tissue has previously been determined 
to be 1 g/ml (16) using tissue weight and volume calculated by insertion in 0.9% NaCl solution. The 
ovarian surface area was calculated assuming that the ovarian volume represented a spherical 
structure.  
 
Statistics 
Microsoft Excel version 14.6.1 was used to analyse the data. The data for each variable for the 
pretreated and non-pretreated groups were symmetrically distributed with similar variances 
between group 1 and group 2, hence Student’s t-tests assuming equal variance were performed to 
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compare between-group means of follicular density, ovarian volume and number of ovarian cortex 
pieces (17). Age-adjusted comparisons were not performed due to the similar age characteristics 
(mean, median, IQR, range) between two groups. P-values lower than 5% were considered 
statistically significant throughout the study. Quadratic regression curves were fitted to the data 
for both groups in order to visualise the similarities and differences reported (Figs 1 and 2), and in 
order to estimate the age-related loss in ovarian reserve following treatment (Table 2). 
 
Ethical approval 
The project of ovarian tissue cryopreservation was approved by the ethical Committee of 
Copenhagen and Frederiksberg (H-2-2001-044). The storage and collection of patient data was 
approved by the Ministry of Health (J.no 30-1372) and by the Danish Authorities to comply with 
EU-tissue directive.  
 
Results 
There was no significant difference in mean age (±SD) between group 1 and group 2 (13.2 
±4.1 vs 11.6 ±4.3 years; p=0.19, Supplementary Figure 1). Cancer diagnoses for patients in 
the two groups are listed in Table 1. In group 1, the most frequent diagnoses were Hodgkin's 
lymphoma (n=8) and Ewing sarcoma (n=6), while hematological malignancies (acute 
lymphoblastic leukemia and acute myeloid leukemia, n=14) were the most frequent in group 
2. The chemotherapy regimens used in group 2 were all classified as having a low or moderate 
gonadotoxic impact as for instance low dose alkylating agents. However, it has not been 
possible to recover the actual cancer treatment administered prior to excision of ovarian 
tissue. In all 63 one-sided oophorectomy was performed to harvest ovarian tissue. No surgical 
complication was reported in connection with oophorectomy. 
There was no significant difference in follicular density in the ovarian cortex between patients 
who received first-line chemotherapy prior to OTC and patients who did not (p>0.10)(Figure 
1). In contrast, the ovarian volume was significantly higher in group 1 than in group 2 (mean 
±SD 5.3 ±3.3 vs 2.9 ±2.1 ml, p<0.05) (Figure 2). Similarly, the total number of ovarian 
cortex chips cryopreserved was higher in patients who did not receive cancer treatment before 
ovary removal (mean ±SD 21.3 ±8.1 vs 15.2 ±7.1, p<0.05)(Supplementary Figure 2). The 
ovarian surface area was calculated assuming that the volume represents a spherical 
structure. The pool of primordial follicles is situated approximately one millimeter below the 
ovarian surface epithelium and the surface area therefore represents the ovarian pool. Further, 
this applies to both groups since the average estimated follicular density was similar between 
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the two groups. After cancer treatment the estimated ovarian surface area was reduced by 
around 10% in young girls and around 30% in adolescent girls (Table 2).   
 
 
Discussion 
The current study found no significant differences in terms of follicular density between young 
girls who received first-line chemotherapy before OTC and those who did not. On the other hand, 
the ovarian volume and the total number of ovarian cortex pieces were significantly reduced by 
cancer treatment received before OTC. Thus, the ovarian reserve and the future fertility potential, 
could – depending on age – be reduced by the first-line chemotherapy by almost 30% in girls 10—
18 years of age. In this study patients who received low-risk treatment initially did not receive 
fertility preservation but were referred to OTC following relapse that required intensive cancer 
treatment with high gonadotoxicity justifying OTC. The cryopreservation process of freezing and 
transplantation of ovarian tissue is far from efficient – only a fraction of the transplanted follicles 
survive the entire process and becomes available to the patient. However, young girls lose only of 
average 10% of their pool, which is a low reduction and may be without long-term consequences 
for fertility. Some of the adolescent girls, who may lose around 30% of the pool of follicles, could 
in some cases be considered differently and would have benefitted from having had OTC 
performed initially, rather than after gonadotoxic treatment with only 70% of the original pool of 
follicles left, as this study suggests. However, the fact that relapse would occur was unforeseen in 
the first place. The present new information provides potential support for the patient and her 
parents. The information may qualify the difficult decision on whether to offer OTC to patients 
undergoing low-risk cancer treatments or only offering it to patients who are undergoing 
intensified chemotherapy. 
We acknowledge that our study has limitations. The first-line treatments for group 2 are not 
homogeneous, although they are all estimated to be mildly or moderately gonadotoxic. All acute 
leukemia cases are in group 2, meaning that specific comparisons involving ALL and AML are not 
available from our data. The measurement of AMH in both groups would have had a positive 
contribution to our analyses and comparisons.  
In light of the increased long-term survival of childhood cancer, counselling about fertility 
preservation is now recommended to be offered to young patients and their parents  prior to any 
cancer treatment (18). The OTC is the only option available in girls and young women where 
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ovarian stimulation for oocyte/embryo cryopreservation is considered inappropriate. A substantial 
heterogeneity of inclusion criteria exists, not only worldwide, but also within single countries 
showing that the selection of patients for OTC is a new emerging area, where actual clinical 
experience is scarce especially considering the effect of transplantation. The procedure is usually 
offered when there is a high risk of POI (> 50%). However, in one of the largest cohorts of OTC in 
girls younger than 16 years, Jadoul and co-workers (19) demonstrated that it is difficult to 
estimate the risk of infertility, whereas Wallace and co-workers had success in predicting the 
gonadotoxic insult by a given cancer treatment (11, 20). It is possible to define treatment regimens 
as low-, medium- and high-risk for ovarian toxicity, but disease evolution is never totally 
predictable and currently an individual assessment is required in each individual case (19-21). An 
interesting avenue of future investigation based on similar data would be the comparison of 
ovarian characteristics following intensive chemotherapy for Ewing's (with ifosfamide) as opposed 
to treatment for ALL with much less exposure to alkylating agents. 
Clinically the consequences of an up to 30% reduction of the ovarian reserve in young girls are not 
known. It is likely that the fertility potential is not significantly reduced in perhaps the first decades 
of life, but the risk of POI and infertility is related to the different treatment regimens. However, in 
order to preserve fertility later in life, oocytes or embryos can be cryostored when there still is a 
follicular reserve after recovery. Of course this requires additional treatment, which potentially 
could have been avoided.  
Further, very little is known about the pre-pubertal ovary and the mechanisms occurring during 
the transition from childhood through puberty to adulthood. In the young ovary, the follicular 
density is higher (15, 22), and follicles in early stages of development are present both in the 
cortex and in the medulla (23, 24). A recent paper showed that ovarian tissue from pre-pubertal 
girls contains a large population of abnormal primordial follicles that are lost in adolescence (25). 
Moreover, immature follicles collected from pre-pubertal ovarian tissue may have a more limited 
capability of follicular development than those retrieved from adult tissue (25-28). Similarly, data 
about the ovarian volume and follicle distribution are very limited in young girls and adolescents. 
According to a normative model, the ovarian volume enlargement occurs through childhood and 
adolescence to reach the maximum volume at 20 years of age, thereafter declining towards the 
menopause and beyond (29); with respect to this model our non-treated volumes are close to the 
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predicted values and the treated volumes are substantially smaller.  Antineoplasic drugs generally 
affect the growing follicles, but are also able to raise the recruitment of non-growing follicles and 
damage the ovarian vascularization in the stromal tissue with a detrimental effect on the ovarian 
reserve (30). These observations obviously make it even more difficult to evaluate the mechanisms 
of gonadotoxicity in young and adolescent girls and make the actual estimations of the 
gonadotoxic insult of the present paper important. Further, it is interesting to notice that the 
follicular density remains similar between the two groups (with densities for both groups close to 
predicted values from a normative model (31)), while the ovarian volume is reduced in the treated 
group. Perhaps the follicular density and overall three dimensional environment is important for 
determining initiation of follicular growth and recruitment of interstitial cells to theca cell layer 
(32).  
Patients in group 2 who received cancer treatment prior to OTC in the majority of cases had a 
diagnosis of leukaemia. However, there are no leukemic patients in group 1 and it is not possible 
to directly evaluate the gonadotoxic insult by the pretreatment given to leukemic patients. 
However, the pretreatment given to leukemic patients is usually not considered to exert a strong 
gonadotoxic effect. This may be different with Ewing and other types of sarcoma, where 
pretreatment may include alkylating agents. However, there is no statistical significant difference 
between the follicular density of patients who did or did not receive pretreatment with this 
diagnosis. There is probably considerable inter individual variations and a larger data set is 
possibly required to unravel to potential differences in the gonadotoxic insult caused by specific 
regimes.  
 
In conclusion, in girls under the age of 10 years first-line cancer treatment does not compromise 
the ovarian reserve with more than 10%. In contrast, adolescent girls between 11—18 years may 
experience an estimated reduction of 30% of their ovarian reserve. The precise long-term 
consequences of having a 30% reduced ovarian reserve are not known today but the information 
is important in the counseling of the young patients and their parents and to determine whether 
fertility preservation should be performed or not. 
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Figure legends 
 
Figure 1. Follicular density in ovarian cortex. 
There was no significant difference in follicular density in ovarian cortex from patients who did or 
did not receive first-line antineoplastic treatment. The lines are quadratic best-fit to the data for 
the two groups. 
 
 
Figure 2. Ovarian volume. 
The ovarian volume was significantly reduced by previous antineoplastic treatment as compared 
to those who did not receive pre-treatment (p< 0.05). The lines are quadratic best-fit to the data 
for the two groups. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
